MN Wealth Advisors LLC Sells 8,097 Shares of Pfizer Inc. (NYSE:PFE)

MN Wealth Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 23.6% during the third quarter, HoldingsChannel reports. The fund owned 26,212 shares of the biopharmaceutical company’s stock after selling 8,097 shares during the quarter. MN Wealth Advisors LLC’s holdings in Pfizer were worth $759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FAS Wealth Partners Inc. increased its holdings in Pfizer by 1.3% in the 2nd quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock valued at $736,000 after buying an additional 342 shares during the period. Sachetta LLC increased its holdings in Pfizer by 7.3% in the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 342 shares during the period. Ironvine Capital Partners LLC increased its holdings in Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 353 shares during the period. Secure Asset Management LLC increased its holdings in Pfizer by 0.6% in the 2nd quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock valued at $1,632,000 after buying an additional 353 shares during the period. Finally, Patrick M Sweeney & Associates Inc. increased its holdings in Pfizer by 0.8% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 355 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.3 %

Pfizer stock opened at $29.46 on Wednesday. The company’s 50 day simple moving average is $29.02 and its 200 day simple moving average is $28.41. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The firm has a market capitalization of $166.94 billion, a price-to-earnings ratio of -491.00, a PEG ratio of 1.30 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.70%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Get Our Latest Research Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

• Five stocks we like better than Pfizer
• What is the Shanghai Stock Exchange Composite Index?
• Bright Minds Biosciences Stock Surges Almost 1,500%
• Do ETFs Pay Dividends? What You Need to Know
• Charles Schwab: Steady Performance, But Is There More to Come?
• Canadian Penny Stocks: Can They Make You Rich?
• Realty Income: A Dividend Powerhouse With Growth Potential

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).